Treatment with fitusiran prophylaxis led to a lower rate of bleeding events and an improved health-related quality of life in patients with haemophilia A or B with inhibitors. The observed safety profile of fitusiran in the phase 3 ATLAS-INH trial was favourable and consistent with previous phase 1 and 2 studies in patients with severe haemophilia .
“Patients with severe haemophilia can develop inhibitors against factor VIII or IX, preventing factor replacement therapy from working,” said Dr Guy Young (University of Southern California, CA, USA). “A quarter of patients develops these inhibitors, leading to a worse prognosis. Novel agents are needed to protect these patients from bleeding events and arthropathy, and improve their quality of life. In addition, the current IV therapies need to be administered multiple times per week, resulting in venous access issues and poor adherence.” Fitusiran is an investigational, subcutaneous, small interference RNA therapeutic targeting antithrombin. In the phase 3 ATLAS-INH trial (NCT03417102), patients with haemophilia A or B with inhibitors were randomised 2:1 to fitusiran therapy (80 mg, subcutaneous, once monthly; n=38) or on-demand bypassing agents (BPA; n=19). The primary endpoint was the annual bleeding rate after 9 months.
The median annual bleeding rate for patients in the fitusiran arm was 0.0, compared with 16.8 in the BPA on-demand arm. In addition, 65.8% of the patients treated with fitusiran displayed no bleeding events during the study. In the BPA on-demand group, only 5% of the patients had no bleeding events. The Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) demonstrated a meaningful improvement in total score in patients treated with fitusiran (mean change -15.27), whereas patients in the BPA on-demand group did not show improvement in quality of life (mean change -0.42).
The safety analysis did not reveal new risks associated with fitusiran therapy. There were 11 patients with observed treatment-emergent adverse events (AEs) of special interest in the fitusiran group and 0 in the BPA on-demand group. The treatment-emergent AEs of special interest included 11 cases of mildly to moderately increased transaminases and 2 thromboembolic events. One patient in the fitusiran arm discontinued the study.
In conclusion, fitusiran was safe and efficacious in patients with severe haemophilia with inhibitors, demonstrating strongly reduced bleeding rates and improved quality of life scores in these patients.
- Young G, et al. Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI). Abstract 4, ASH 2021 Annual Meeting, 11–14 December.
Copyright ©2022 Medicom Medical Publishers
« rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors Next Article
Fitusiran meets primary endpoint in ATLAS-A/B trial »
Table of Contents: ASH 2021
Letter from the Editor
ASH 2021 Highlights Podcast
Acute Lymphoblastic Leukaemia
New Interfant protocol includes blinatumomab for KMT2A-r ALL
Persistent disparities in ALL health outcomes
EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL
UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL
Acute Myeloid Leukaemia
AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML
Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients
Promising frontline triplet regimen for TP53-mutated AML
Encouraging results of novel triplet combination for AML
Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
Benefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML
Improved risk stratification in MDS via gene-based scoring system
CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL
SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL
Investigational therapies superior to standard-of-care in double-exposed CLL
GRIFFIN: Sustained responses of daratumumab plus RVd in MM
MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM
iStopMM: Smouldering MM highly prevalent in general population
Mechanisms of D-KRd treatment failure in MM identified
TRIMM-2: Favourable results of talquetamab plus daratumumab for MM
Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma
Axi-cel improved event-free survival in R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in DLBCL
POLARIX: Novel regimen superior to R-CHOP in DLBCL
Novel non-invasive biomarker ctDNA shows value in CNS lymphoma
Mechanisms behind TP53 mutations revealed in myeloproliferative neoplasms
JAK2V617F variant allele frequency prognostic of venous events in polycythaemia vera
Promising results of tacrolimus plus dexamethasone for ITP
Sustained remission after TPO-RA discontinuation in chronic ITP
Fitusiran meets primary endpoint in ATLAS-A/B trial
ATLAS-INH: Impressive results of fitusiran for haemophilia with inhibitors
rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors
Reduced risk of Alzheimer’s disease in CHIP carriers
Lifelong patterns of clonal haematopoiesis revealed
Reduced risk of Alzheimer’s disease in CHIP carriers